Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis
Paolo Gisondi, Davide Geat, Andrea Conti, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 6, pp. 591-598
Closed Access | Times Cited: 25

Showing 25 citing articles:

Gasdermin E-mediated keratinocyte pyroptosis participates in the pathogenesis of psoriasis by promoting skin inflammation
Yingfei Li, Yi He, Fangyuan Yang, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 3, pp. 385-396
Open Access | Times Cited: 9
Amlexanox ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting Th17 cells and the NF-κB signal pathway
Juan Wu, Shan Liu, Hongwei Zhang, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 184, pp. 117922-117922
Open Access | Times Cited: 1
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Biologics (2021) Vol. Volume 15, pp. 247-253
Open Access | Times Cited: 48
Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling
Chujun Ma, Chaode Gu, Panpan Lian, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 11
Open Access | Times Cited: 21
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 495-495
Open Access | Times Cited: 8
Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways
Husna Kadagothy, Shweta Nene, Etikala Amulya, et al.
European Journal of Pharmacology (2023) Vol. 947, pp. 175668-175668
Closed Access | Times Cited: 11
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Giampiero Girolomoni, L. Savage, Paolo Gisondi, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2171-2185
Open Access | Times Cited: 8
Development of selective heterocyclic PDE4 inhibitors for treatment of psoriasis
Gang Li, Dengqin He, Xudong Qian, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116930-116930
Closed Access | Times Cited: 2
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
Francesco Bellinato, Paolo Gisondi, Elena Jane Mason, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1303-1311
Open Access | Times Cited: 10
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
Paolo Gisondi, Davide Geat, Patrizio Armeni, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1579-1584
Closed Access | Times Cited: 10
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
Martina Maurelli, Giampiero Girolomoni, Paolo Gisondi
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 5
Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective
Javier P. Gisbert, Karl Gaffney, David Young, et al.
Expert Opinion on Biological Therapy (2021) Vol. 22, Iss. 2, pp. 109-121
Open Access | Times Cited: 12
Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars
Francesca Prignano, Jaeyun Choi, Burkhard Pieper, et al.
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 1, pp. 75-80
Open Access | Times Cited: 12
Tailored biological treatment for patients with moderate-to-severe psoriasis
Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni
Expert Review of Clinical Immunology (2022) Vol. 19, Iss. 1, pp. 37-43
Closed Access | Times Cited: 8
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
Paolo Gisondi, Davide Geat, Martina Maurelli, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 646-646
Open Access | Times Cited: 7
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
Marco Matucci‐Cerinic, Francesco Ciccia, Rosario Foti, et al.
Rheumatology and Immunology Research (2024) Vol. 5, Iss. 1, pp. 49-56
Open Access | Times Cited: 1
Design, Synthesis, and Biological Evaluation of New Selective PDE4 Inhibitors for Topical Treatment of Psoriasis
Dengqin He, Gang Li, Jia‐Qiang Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20353-20371
Closed Access | Times Cited: 1
The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis
Chiara Gasteiger, Alfons A den Broeder, Sarah Stewart, et al.
Health Psychology Review (2021) Vol. 17, Iss. 1, pp. 148-168
Open Access | Times Cited: 9
Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics
Francesca Prignano, Leonardo Pescitelli, Emanuele Trovato, et al.
Italian Journal of Dermatology and Venereology (2022) Vol. 157, Iss. 6
Closed Access | Times Cited: 6
Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review
I. Belinchón, Almudena Mateu Puchades, Miguel Ribera Pibernat, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 1335-1345
Open Access | Times Cited: 3
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial
А. В. Самцов, А. Л. Бакулев, В. Р. Хайрутдинов, et al.
PLoS ONE (2022) Vol. 17, Iss. 2, pp. e0263214-e0263214
Open Access | Times Cited: 5
Innate Immune Responses to Sporothrix schenckii: Recognition and Elimination
Lin Peng, Jianfeng Zhang, Guinan Xie, et al.
Mycopathologia (2022) Vol. 188, Iss. 1-2, pp. 71-86
Closed Access | Times Cited: 3
Current Landscape of Chronic Inflammatory Dermatoses: Where We Are and Where We Are Heading
Aleksandra Sójka, Piotr Krajewski
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 9, pp. 10259-10263
Open Access
Advances in Psoriasis Treatment: Emerging Therapeutic Strategies
Azhar Jabbar Khalaf Al-Subaihawi, Tamarah Gays Almohammedi, Nada Hamzah Shareef Al-Shabbani
European Journal of Medical and Health Research (2024) Vol. 2, Iss. 6, pp. 58-68
Closed Access
Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling
Hongwei Wang, Chujun Ma, Ziqi Peng, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top